Clinical Trial Update: Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating apixaban for acute symptomatic deep vein thrombosis has completed. This Botticelli DVT study update summarizes the trial status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Deep-Vein Thrombosis | Phase 2 | Status: COMPLETED